Formation Minerals

Formation Minerals EBITDA per Share

The EBITDA per Share of Formation Minerals (FOMI) as of Oct 22, 2026 is -0.02 USD. In the previous year, EBITDA per Share was -0.01 USD — a change of 49.26% (lower).

EBITDA per Share

-0.02USD

YoY

49.26%

Last updated:

EBITDA per Share of Formation Minerals is 2024 -0.02 USD. EBITDA per Share of Formation Minerals was 2023 -0.01 USD. It decreases by 49.26% lower compared to the previous year.

The Formation Minerals EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2021
-0.02 USD
Jan 1, 2022
-0.02 USD
Jan 1, 2023
-0.01 USD
Jan 1, 2024
-0.02 USD
The Formation Minerals EBITDA per Share history
YEAREBITDA per ShareYoY
-0.02USD+49.26%
-0.01USD-18.66%
-0.02USD-7.31%
-0.02USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Formation Minerals Stock analysis

What does Formation Minerals do? SensaSure Technologies, Inc. generates revenue by commercializing its ExaBreath (EB) device and method, which are designed to transform the collection of biological samples for lab-based analysis. The company focuses on supplying a non-invasive solution that collects, extracts, detects, and identifies non-volatile compounds present in every exhaled breath. This approach utilizes existing lab-based testing infrastructure and procedures, allowing the firm to offer a product that enhances the user experience across various applications and markets. The primary value proposition lies in the ability to detect a range of exogenous substances, including drugs of abuse, therapeutic drugs, and performance-enhancing drugs, without requiring invasive collection methods. The company targets specific segments such as workplace drug testing, anti-doping in sports, law enforcement, e-health, and telemedicine. By applying its ExaBreath methodology to toxicology, pharmacology, and clinical biochemistry, SensaSure Technologies, Inc. provides a tool for disease detection, exposure monitoring, and drug metabolism analysis. The firm's offerings are tailored to meet the needs of these diverse sectors, ensuring that the device can effectively identify narcotics, antibiotics, and stimulants. This broad applicability allows the company to serve multiple industries that require reliable and non-invasive chemical detection in breath samples. Revenue is driven by the commercialization of the ExaBreath product, which is marketed to entities involved in the aforementioned segments. The company leverages its headquarters in New York City, New York, to support its operations and distribution of the device and method. By focusing on the validation and development of the ExaBreath technology, SensaSure Technologies, Inc. positions itself as a provider of innovative solutions for biological sample collection. The firm's strategy centers on expanding the use of its non-invasive testing methodology across different markets, thereby creating multiple revenue streams from the sale and licensing of its technology. Formation Minerals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Formation Minerals stock

EBITDA per Share of Formation Minerals is -0.02 USD in 2024.

EBITDA per Share of Formation Minerals changed from -0.01 USD to -0.02 USD, representing a 49.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Formation Minerals since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Formation Minerals

All Key Metrics — Formation Minerals